Schaeffers Research
26 Aug 2026, 18:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Short interest in Novavax has risen to 29% of the stock's available float. — High short interest indicates strong institutional conviction that the stock is overvalued or facing fundamental headwinds.
-0.60Options traders have purchased 29,000 put options, which is 32 times the average daily rate. — A massive spike in put buying suggests a sudden shift toward bearish sentiment and hedging against a price drop.
-0.50Novavax's skin cancer vaccine trials conducted with Moderna showed positive results. — Positive clinical trial outcomes provide a fundamental catalyst for long-term growth and valuation increases.
+0.40The stock's put/call open interest ratio (SOIR) of 0.13 sits in the 10th percentile of its annual range. — Extreme bullishness in open interest suggests strong near-term optimism, though it also creates risk if the trend reverses.
Continue reading
6 related stories
Search tags
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Barrons
4h ago
